Pharmaceuticals - Switzerland

Switzerland

The Pharmaceuticals market in Switzerland is expected to achieve a revenue of US$6.90bn in 2024.
Among the various markets, Oncology Drugs is projected to be the largest with a market volume of US$1.21bn in the same year.
The market is anticipated to grow at an annual rate of 4.96% (CAGR 2024-2029), resulting in a market volume of US$8.79bn by 2029.
When compared globally, United States is forecasted to generate the highest revenue of US$630.30bn in 2024.
Switzerland, known for its strong pharmaceutical industry, continues to lead in innovative research and development.

Key regions: United States, China, Germany, Japan, Europe

Definition:
The Pharmaceuticals market covers remedies used to cure, treat, prevent, and diagnose diseases. These small molecule drugs or biologic medical products may be called drugs, medications, or medicines. Prescription drugs and over-the-counter (OTC) drugs are both included. Depending on the regulations in each country, these products are provided by pharmacies, hospitals, physicians, and/or drug stores, and/or they can be bought elsewhere. They may be administered in the form of pills, capsules, gels, ointments, injections, infusions, lozenges, or aerosols/sprays.

Structure:
The market is subdivided into Oncology Drugs, Anti-Diabetes Drugs, Anti-Rheumatic Drugs, Vaccines, Dermatological Drugs, Antiviral Drugs, Immunosuppressants, Bronchodilator Drugs, Sensory Organ Drugs, Anti-Hypertensive Drugs, Anti-Coagulants, Anti-Fibrinolytic Drugs, Multiple Sclerosis Drugs, Lipid-Lowering Agents and Other Pharmaceuticals. The Pharmaceuticals market is organized in markets that cover drugs used in specific medical fields, i.e., medicines for a specific disesase or a certain type of medicine. They include original brands, biosimilars, generics, and orphan drugs.The Oncology Drugs market covers pharmaceutical products specifically developed for the treatment and management of various cancers. The Anti-Diabetes Drugs market covers medications designed to manage blood glucose levels and improve insulin sensitivity in individuals with diabetes. The market Anti-Rheumatic Drugs includes pharmaceuticals specifically developed to alleviate symptoms, reduce inflammation, and modify the progression of rheumatic diseases. The Dermatological Drugs market covers pharmaceuticals formulated to treat and manage a wide range of skin conditions such as eczema, acne, and rosacea. The Antiviral Drugs market includes medications designed to treat viral infections and reducing the severity and duration of symptoms. The Immunosuppressants market covers pharmaceuticals that suppress the immune system's activity. The Bronchodilator Drugs market covers pharmaceuticals designed to relax and widen the airways in the lungs. The Sensory Organ Drugs market covers pharmaceuticals targeting the treatment of disorders and conditions affecting sensory organs such as the eyes, ears and nose. The Anti-hypertensive Drugs market covers pharmaceuticals designed to lower blood pressure levels. The Anti-Coagulants Drugs market covers pharmaceuticals developed to prevent the formation of blood clots or to dissolve existing clots. The Anti-Fibrinolytics Drugs market covers pharmaceuticals designed to inhibit the breakdown of blood clots. The Multiple Sclerosis Drugs market covers pharmaceuticals aimed at managing and modifying the course of multiple sclerosis. The Lipid-Lowering Agents market covers pharmaceuticals developed to reduce levels of cholesterol and other lipids in the blood. The Other Pharmaceuticals market provides information on additional specialties that are not covered by the main markets.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novartis, Roche, Pfizer, Merck & Co, Johnson & Johnson, AbbVie, Sanofi.

Market

Region

Region comparison

Currency

Analyst Opinion

Switzerland is known for its strong pharmaceutical industry, with several global pharmaceutical companies headquartered in the country. The market has been developing steadily in recent years, driven by various factors.

Customer preferences: Swiss consumers place a high value on healthcare and are willing to pay a premium for quality products. They prefer pharmaceuticals that are effective, safe and have minimal side effects. Additionally, there is a growing preference for natural and organic products, which has led to an increase in demand for herbal and homeopathic medicines.

Trends in the market: One of the major trends in the Swiss pharmaceutical market is the increasing use of digital technology in healthcare. Digital health solutions such as telemedicine, mobile health apps, and wearables are becoming more popular among patients and healthcare providers. This trend is expected to continue in the coming years, driven by the need for more efficient and cost-effective healthcare services.Another trend in the market is the growing focus on personalized medicine. Advances in genomics and other technologies are enabling the development of targeted therapies that are tailored to individual patients. This trend is expected to drive innovation in the industry and lead to the development of more effective treatments.

Local special circumstances: Switzerland has a highly skilled workforce and a strong research and development infrastructure, which has helped to attract pharmaceutical companies to the country. The Swiss government also provides significant support for research and development in the industry, which has helped to foster innovation.However, the country's high cost of living and labor costs can make it challenging for smaller companies to compete in the market. Additionally, the country's strict regulatory environment can make it difficult for companies to bring new products to market.

Underlying macroeconomic factors: Switzerland has a stable and prosperous economy, which has helped to support the growth of the pharmaceutical industry. The country's high standard of living and strong healthcare system have also contributed to the demand for pharmaceutical products.However, the country's aging population and rising healthcare costs are creating challenges for the industry. As the population ages, there is an increasing demand for healthcare services, which is driving up costs. This trend is expected to continue in the coming years, which could put pressure on the industry to develop more cost-effective solutions.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.